Positron Ventures

Thorizon is a deep-tech startup spun off from the Dutch Nuclear Research Institute, with offices in Amsterdam and Lyon. It is developing thorium molten salt reactor technology designed to provide a responsible, carbon-free energy source by using long-lived nuclear waste and thorium as fuel, with a focus on safety and circularity. The company aims to deliver a scalable demonstration and to begin constructing a first-of-a-kind reactor by 2030, named Thorizon One. It collaborates with industry leaders including Orano, Tractebel, and EDF and has been recognized as a laureate in the France 2030 program for advanced nuclear projects.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Renaissance Fusion is a company focused on the development of high-temperature superconductors aimed at making fusion electricity affordable and enhancing medical imaging techniques, particularly MRI. By providing advanced superconductors for plasma devices, the company seeks to simplify the stellarator technology, thereby facilitating the integration of fusion energy into the power grid. This innovation not only aims to lower the costs associated with fusion electricity but also promotes the use of MRI as a standard method of medical examination, contributing to improved healthcare accessibility.

Thorizon is a deep-tech startup spun off from the Dutch Nuclear Research Institute, with offices in Amsterdam and Lyon. It is developing thorium molten salt reactor technology designed to provide a responsible, carbon-free energy source by using long-lived nuclear waste and thorium as fuel, with a focus on safety and circularity. The company aims to deliver a scalable demonstration and to begin constructing a first-of-a-kind reactor by 2030, named Thorizon One. It collaborates with industry leaders including Orano, Tractebel, and EDF and has been recognized as a laureate in the France 2030 program for advanced nuclear projects.

CimCure specializes in developing novel active cancer immunotherapies. It focuses on creating cancer vaccines using its proprietary Immune-Boost-tailored conjugate vaccination technology, enabling doctors to more effectively treat and suppress tumor growth.

Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

Thorizon is a deep-tech startup spun off from the Dutch Nuclear Research Institute, with offices in Amsterdam and Lyon. It is developing thorium molten salt reactor technology designed to provide a responsible, carbon-free energy source by using long-lived nuclear waste and thorium as fuel, with a focus on safety and circularity. The company aims to deliver a scalable demonstration and to begin constructing a first-of-a-kind reactor by 2030, named Thorizon One. It collaborates with industry leaders including Orano, Tractebel, and EDF and has been recognized as a laureate in the France 2030 program for advanced nuclear projects.

Qu&Co is a prominent startup specializing in quantum-computational algorithm and software development, focusing on optimizing specialty chemicals, pharmaceuticals, and functional materials. The company creates software that enhances in-house discovery and optimization processes by advancing innovative quantum-computational chemistry methods. This technology integrates seamlessly into existing chemistry and material-science workflows, allowing industries such as pharmaceuticals to conduct complex chemistry and multiphysics simulations on future quantum processors. In January 2022, Qu&Co merged with PASQAL, a leader in neutral atom-based quantum hardware, solidifying its position as a key player in the European quantum computing landscape.